Investigating Methylation to Explain Gene Expression Patterns between Glioblastoma and Alzheimer's Disease
CSEF · 2017 Computational Systems & Analysis
Overview
Objectives/Goals Studies show inverse correlation between Alzheimer#s Disease(AD) and Glioblastoma(GBM), both diseases of the brain. AD and GBM are both associated with epigenetic factors. Can epigenetics explain this correlation? Can cancer or AD drugs, that treat via methylation, cause higher risk of the other disease? Methods/Materials Laptop, Excel. Inputs: results of past studies done on AD, GBM and Epigenetics. These results were published in journals (Nature, JAMA), or reports from GDAC for GBM. AD inputs are genes, CpGs, DMR (differentially methylated regions) and SNPs (single nucleotide polymorphisms). GBM inputs are genes related to clinical features and CpG methylation. Genes correlated with AD and GBM are tested to see if methylation is significant for AD, GBM or both (p-value < 5E-04) Results AD and GBM genes are divided into 4 categories depending on methylation significance (AD and GBM, AD only, GBM only, none). Four genes (MGMT, PPT2, SMC1B, MTCH2) show significant methylation in both GBM and AD with CpG features (island, shore and promoter). These genes are inversely expressed in AD and GBM. MTCH2 has been studied for breast cancer and needs additional study for GBM. The genes SMC1B and PPT2 need further study to identify the role in AD/GBM. Conclusions/Discussion 4 genes (MGMT, PPT2, SMC1B, MTCH2) have significant methylation and are inversely expressed in AD and GBM. MGMT, which repairs DNA damage, is shown to be correlated with AD in cerebrospinal fluid. Methylation of the promoter region of MGMT has shown direct correlation with GBM. DNA methylation in MGMT is targeted by GBM drug, TMZ or Temozolomide. Further clinical study is needed to identify AD risk factors in patients treated by TMZ.
Summary statement
My research shows significant methylation of 4 genes that have inverse correlation in Glioblastoma and Alzheimer's Disease.
Help received
None. I downloaded data for GBM from GDAC and from research papers for AD. I compared the results with previously published work.
Competition history
- CSEF 2017
Resources
Related projects
ISEF · 2014
Discovery of Significant Tissue Specific DNA Methylation Patterns and Motif Analysis in NPAS3 Gene in Schizophrenia-Diseased Individuals
CSEF · 2017
Identification of Diagnostic Biomarkers and Therapeutic Targets across Adenocarcinomas Using DNA Methylation Analyses
CSEF · 2014
Targeted Cancer Therapy and Diagnosis: Analyzing miRNA Expression Signatures & Interactions for Glioblastoma Progression
ISEF · 2023
Identification of Cell-Free DNA Methylation Signatures as a Potential Genomic Biomarker of Alzheimer's Disease
ISEF · 2024
Identification of Novel Target Genes and ML-Based Drug Repurposing and Discovery for Alzheimer’s Disease in the Presence of Metabolic Comorbidities
ISEF · 2015
Identifying DNA Methylation Variation Patterns for Breast Cancer Biomarker Genes
CSEF · 2017
Genome-Based Discovery of Novel CpG Biomarkers for Early Diagnosis and Prognosis of Leukemia
CSEF · 2018
The Application of Exosomes for Diagnostics and Prognostics in Brain Tumors: Medulloblastoma and Glioblastoma
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects